Sjögren's Disease is a chronic autoimmune condition that causes debilitating fatigue, joint pain, and dryness—and has long been undertreated. Dazodalibep is a new biologic launching into a crowded field of competitors arriving at roughly the same time. The brief called for a global HCP launch campaign that could rise above a feature-vs-feature battle and position dazodalibep not as just another option, but as the therapy that sets a new standard of care.
This is spec pitch work developed as part of a competitive RFP response. It is not produced or approved promotional material.
